These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35663288)

  • 1. Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients.
    Dioverti MV; Gaston DC; Morris CP; Huff CA; Jain T; Jones R; Anders V; Lederman H; Saunders J; Mostafa HH; Avery RK
    Open Forum Infect Dis; 2022 Jun; 9(6):ofac064. PubMed ID: 35663288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies.
    Shimizu A; Shirai I; Ogawa K; Miura A; Haruhara K; Oshiro K; Hamaguchi A; Yokote S; Okabe M; Ueda H; Tsuboi N; Ikeda M; Yokoo T
    Intern Med; 2022 Dec; 61(24):3703-3708. PubMed ID: 36171121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies.
    Vellas C; Del Bello A; Gaube G; Tremeaux P; Jeanne N; Ranger N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Open Forum Infect Dis; 2022 Apr; 9(4):ofac093. PubMed ID: 35299988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience.
    Moriello NS; Buonomo AR; Scotto R; Pinchera B; Sarno M; Fusco L; Viceconte G; Iuliano A; Zappulo E; Foggia M; Villari R; Gentile I
    Heliyon; 2023 Feb; 9(2):e13126. PubMed ID: 36713627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Efficacy of Imdevimab/Casirivimab for Persistent Omicron SARS-CoV-2 Infection in Patients with Hematological Malignancies.
    Hagihara M; Hayashi H; Nakashima S; Imai Y; Nakano H; Uchida T; Inoue M; Sakai-Tagawa Y; Ito M; Yamayoshi S; Iwatsuki-Horimoto K; Suzuki Y; Kawaoka Y
    Intern Med; 2024 Jan; ():. PubMed ID: 38171874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
    Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
    Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2022 Feb; 399(10325):665-676. PubMed ID: 35151397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant.
    Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y
    J Infect Chemother; 2022 Sep; 28(9):1344-1346. PubMed ID: 35637130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
    Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
    Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
    Portal-Celhay C; Forleo-Neto E; Eagan W; Musser BJ; Davis JD; Turner KC; Norton T; Hooper AT; Hamilton JD; Pan C; Mahmood A; Baum A; Kyratsous CA; Kim Y; Parrino J; Kampman W; Roque-Guerrero L; Stoici R; Fatakia A; Soo Y; Geba GP; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM;
    JAMA Netw Open; 2022 Aug; 5(8):e2225411. PubMed ID: 35969402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Casirivimab/Imdevimab: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(17):2047-2055. PubMed ID: 34716907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic.
    Suzuki Y; Shibata Y; Minemura H; Nikaido T; Tanino Y; Fukuhara A; Kanno R; Saito H; Suzuki S; Ishii T; Inokoshi Y; Sando E; Sakuma H; Kobayashi T; Kume H; Kamimoto M; Aoki H; Takama A; Kamiyama T; Nakayama M; Saito K; Tanigawa K; Sato M; Kanbe T; Kanzaki N; Azuma T; Sakamoto K; Nakamura Y; Ohtani H; Waragai M; Maeda S; Ishida T; Sugino K; Tsukada Y; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Watanabe N; Rikimaru M; Kawamata T; Umeda T; Morimoto J; Togawa R; Sato Y; Saito J; Kanazawa K; Iseki K
    Int J Med Sci; 2022; 19(5):834-841. PubMed ID: 35693744
    [No Abstract]   [Full Text] [Related]  

  • 14. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
    Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
    Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
    Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
    Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients.
    Hegazy SK; Tharwat S; Hassan AH
    World J Clin Cases; 2023 Sep; 11(26):6105-6121. PubMed ID: 37731581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect on SARS-CoV-2 viral load using combination therapy with casirivimab/imdevimab and remdesivir.
    Kataria VK; Berhe M; Sandkovsky U
    Proc (Bayl Univ Med Cent); 2022; 35(5):655-657. PubMed ID: 35991712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients.
    Hegazy SK; Tharwat S; Hassan AH
    Open Med (Wars); 2023; 18(1):20230768. PubMed ID: 37588660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of casirivimab/imdevimab in an intensive care unit patient with acute respiratory failure due to SARS-CoV-2 infection.
    Sloan B; Duhaime E; Sandkovsky U; Berhe M
    Proc (Bayl Univ Med Cent); 2022; 35(3):339-341. PubMed ID: 35518791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital.
    Keshishian E; Kuge E; Memmott J; Hasenbalg P; Belford N; Matlock A; Schritter S; Agbayani G; Dietrich T; Santarelli A; Ashurst J
    J Osteopath Med; 2022 Dec; 122(12):635-640. PubMed ID: 36123325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.